Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Freiburg im Breisgau
Clinical trial register · Germany

Clinical Trials in Freiburg im Breisgau, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2873
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Essen 50 Berlin 45 Dresden 29 Cologne 28 Hamburg 26
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca37 Novartis Pharmaceuticals24 AbbVie20 Hoffmann-La Roche15 University Hospital Freiburg14 Clear sponsor filter
Site location
Essen50 Berlin45 Dresden29 Cologne28 Hamburg26
All 115 locations
Target enrolment
to

Trials with a site in Freiburg im Breisgau

24 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Leipzig, Halle, Jena
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Freiburg im Breisgau, Heidelberg, Ulm
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Freiburg im Breisgau, Frankfurt am Main, Hanover
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Freiburg im Breisgau, Würzburg, Berlin, Herne
2024-06-28
Recruiting
Novartis Pharmaceuticals
Phase 3
1,444
Freiburg im Breisgau, Munich, Regensburg, Weiden in Der Oberpfalz, Langen, Hildesheim, Bergisch Gladbach, Bielefeld
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Freiburg im Breisgau, Munich, Hamburg, Göttingen, Stade, Dresden, Leipzig, Halle
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Active, closed
Novartis Pharmaceuticals
Observational
436
Freiburg im Breisgau, Rheinstetten, Haßfurt, Kulmbach, Lauf an der Pegnitz, Nuremberg, Panketal, Hamburg
2023-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Freiburg im Breisgau
2023-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Frankfurt am Main, Freiburg im Breisgau
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Freiburg im Breisgau, Mannheim, Munich, Würzburg, Frankfurt am Main, Marburg, Paderborn, Velbert
2022-11-21
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Freiburg im Breisgau
2022-10-24
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Freiburg im Breisgau, Essen, Hamburg
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Freiburg im Breisgau, Göttingen, Bochum
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Heidelberg, Kiel
2021-09-20
Active, closed
Novartis Pharmaceuticals
Phase 2
236
Freiburg im Breisgau, Düsseldorf, Leipzig, Hamburg, Heidelberg
2021-04-19
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Freiburg im Breisgau, Cologne, Dresden, Essen
2021-02-24
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Freiburg im Breisgau, Göttingen, Dresden, Bochum, Erlangen
2013-07-26
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/freiburg-im-breisgau

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Freiburg im Breisgau that also match the filters currently applied.

How many clinical trials are recruiting in Freiburg im Breisgau?

8 of the 24 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Freiburg im Breisgau), 24 studies
PhaseStudiesRecruitingShare
Phase 314558.3%
Phase 1/24116.7%
Phase 24116.7%
Observational104.2%
Phase 2/3114.2%

Most active sponsors

Lead sponsors with the most studies (Freiburg im Breisgau)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals248
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.